Protecting the Next Generation: What Is the Role of the Duration of Human Papillomavirus Vaccine-Related Immunity?

Günther, Oliver P.; Ogilvie, Gina; Naus, Monika; Young, Eric; Patrick, David M.; Dobson, Simon; Duval, Bernard; Noël, Pierre-André; Marra, Fawziah; Miller, Dianne; Brunham, Robert C.; Pourbohloul, Babak
June 2008
Journal of Infectious Diseases;6/15/2008, Vol. 197 Issue 12, p1653
Academic Journal
Background. There is strong evidence that human papillomavirus (HPV) is necessary for the development of cervical cancer. A prophylactic HPV vaccine with high reported efficacy was approved in North America in 2006. Methods. A mathematical model of HPV transmission dynamics was used to simulate different scenarios of natural disease outcomes and intervention strategies. A sensitivity analysis was performed to compensate for uncertainties surrounding key epidemiological parameters. Results. The expected impact that HPV vaccines have on cervical cancer incidence and HPV prevalence in the province of British Columbia in Canada revealed that, for lifelong vaccine-related protection, an immunization routine targeting younger females (grade 6), combined with a 3-year program for adolescent females (grade 9), is the most effective strategy. If vaccine-related protection continues for <10 years, then the targeting of adolescent females would be more beneficial than the targeting of younger females. The incremental benefit if boys, as well as girls, are vaccinated is small. Conclusions. Optimization of the design of immunization strategies for treatment of HPV depends substantially on the duration of vaccine-induced immunity. Given the uncertainty in estimating this duration, it may be prudent to assume a value close to the lower limit reported and adjust the program when more-accurate information for the length of vaccine-induced immunity becomes available.


Related Articles

  • Pricing Human Papillomavirus Vaccines Lessons from Italy. Garattini, Livio; Van De Vooren, Katelijne; Curto, Alessandro // PharmacoEconomics;2012, Vol. 30 Issue 3, p213 

    The article presents the author's views on the Human Papillomavirus (HPV) vaccine prices in Italy. He comments that the coverage of three screening programmes were listed by the Italian Ministry of Health (MoH) recently. He remarks on two linear regressions conducted to examine the correlation...

  • Attitudes about human papillomavirus vaccine in young women. Kahn, Jessica A.; Rosenthal, Susan L.; Hamann, Tara; Bernstein, David I. // International Journal of STD & AIDS;May2003, Vol. 14 Issue 5, p300 

    Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women (n=52, mean age 25 years,...

  • Long-term efficacy and safety of human papillomavirus vaccination. De Vincenzo, Rosa; Conte, Carmine; Ricci, Caterina; Scambia, Giovanni; Capelli, Giovanni // International Journal of Women's Health;2014, Vol. 6, p999 

    In this paper, we review the published evidence about the long-term efficacy of the available human papillomavirus (HPV) vaccines and their safety profile. Two prophylactic HPV vaccines - bivalent (bHPV) and quadrivalent (qHPV) - are now available, and vaccination programs are being widely...

  • Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception? Licht, Andrea S.; Murphy, Jill M.; Hyland, Andrew J.; Fix, Brian V.; Hawk, Larry W.; Mahoney, Martin C. // Sexually Transmitted Infections;Feb2010, Vol. 86 Issue 1, p19 

    Background Few studies have examined factors associated with the actual use of the human papillomavirus (HPV) vaccine since licensure in 2006. The aims of this study were to assess HPV vaccination rates and to examine whether knowledge and risk perceptions regarding HPV were associated with the...

  • HPV vaccine coverage rates equal call to action for providers. Bocchini Jr., Joseph A. // Infectious Disease News;Sep2013, Vol. 26 Issue 9, p7 

    The article reports that no improvement was seen in the coverage rate for Human papillomavirus (HPV) for girls in 2012, which was revealed by the 2012 National Immunization Survey-Teen in a Morbidity and Mortality Weekly Report.

  • Viral vaccines forge ahead. Jesitus, John // Dermatology Times;Jan2008, Vol. 29 Issue 1, p40 

    The article reports on the views of Stephen K. Tyring, professor of dermatology at the University of Texas Health Science Center in Houston, regarding the efficacy of viral vaccines such as the human papilloma virus (HPV) vaccine Gardasil. According to Tyring, the HPV vaccine continues to be...

  • HPV vaccine promises to fight cervical cancer. Perry, Leah // Drug Topics;3/20/2006, Vol. 150 Issue 6, p20 

    The article introduces a new vaccine that could eliminate the human papillomavirus (HPV), thereby aiding in fighting cervical cancer. During clinical trials of GlaxoSmithKline PLC's vaccine named Cervarix in November 2005, the drug had prevented 90 percent of new infections and all persistent...

  • HPV vaccine reduces lesion rate in young men by 60%. Robinson, Stephen // GP: General Practitioner;2/11/2011, p9 

    The article reports on a study which suggests that vaccination of young men with a multi-strain papillomaviruses (HPV) jab reduces the occurrence of genital lesions. Researchers from the University of California, San Francisco, have found that a quadrivalent HPV vaccine prevented 60 per cent of...

  • Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Heterosexual Men. Nyitray, Alan; Nielson, Carrie M.; Harris, Robin B.; Flores, Roberto; Abrahamsen, Martha; Dunne, Eileen F.; Giuliano, Anna R. // Journal of Infectious Diseases;6/15/2008, Vol. 197 Issue 12, p1676 

    In US men, the incidence of anal cancer, the primary cause of which is human papillomavirus (HPV) infection, has increased almost 3-fold in 3 decades; however, little is known about the epidemiology of anal HPV infection, especially in heterosexual men. In 2 US cities, behavioral data and anal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics